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Peginterferon alfa plus ribavirin is currently the treatment of choice for chronic hepatitis C.
Peginterferon alfa-2a (40KD) plus ribavirin has given an overall sustained virological response of
18% in F3/F4 previous nonresponder US patients. We evaluated the effectiveness of peginterferon
alfa-2a (40KD) plus ribavirin in Brazilian patients who were relapsers or nonresponders to previous
interferon-based therapy. One-hundred-thirty-four patients with biopsy-proven chronic hepatitis C,
HCV RNA positive, elevated ALT and who were either relapsers (n=37) or nonresponders (n=97) to at
least 24 weeks of conventional interferon/ribavirin therapy were retreated with peginterferon alfa-
2a (40KD) 180mg/qw and ribavirin 800mg bid for 48 weeks. Efficacy was assessed as virological
response (defined as undetectable HCV RNA) at the end of treatment (EoT) and at the end of follow-
up (SVR - Sustained Virological Response). Safety assessments consisted of clinical and laboratory
evaluations. In the patient sample, 72% were genotype 1 and 34% were cirrhotic. In an intention-to-
treat analysis, relapser patients showed 78% EoT response and 51% SVR. Nonresponders showed
57% EoT response and 26% SVR. Positive predictive factors of SVR were non-1 genotype and relapser
state. Six percent of the patients interrupted treatment because of adverse events and 45% had dose
reduction (mainly associated with leucopenia and anemia). Brazilian patient relapsers and
nonresponders to conventional interferon and ribavirin treatment can achieve a sustained virological
response when retreated with peginterferon alfa-2a (40KD) and ribavirin. The safety profile is
similar to that of naive patients.
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Chronic infection with hepatitis C virus (HCV) is the leading
cause of liver cirrhosis and hepatocellular carcinoma
worldwide [1]. HCV-associated liver disease is the most
common indication for liver transplantation [2]. Therefore, new
therapeutic strategies to avoid the progression of HCV-related
liver disease are eagerly awaited. A 48-week course of
conventional interferon (IFN) therapy at the standard dose of
3 MU tiw combined with ribavirin (1000-1200 mg daily) yielded
a sustained virological response (SVR) of approximately 40%
in naive patients [3,4]. Recently, two randomized controlled
trials have shown that the combination of peginterferon alfa-
2a (40KD) plus the standard dose of ribavirin, or of
peginterferon alfa-2b (12KD) plus a low dose of ribavirin, are
significantly more effective than the combination of
conventional IFN plus ribavirin in previously untreated
patients with an overall SVR of 56% and 54%, compared to
approximately 45%, respectively [5,6]. A later prospective
controlled trial showed that the HCV genotypes and baseline
viral load are also the most important predictive variables to
peginterferon alfa-2a (40KD) and ribavirin combined treatment
in naive patients. The overall sustained virological response
in this trial was 63% [7].
Choosing the correct strategy for retreating chronic
hepatitis C patients, who were nonresponders to a first course
of antiviral therapy, is the biggest challenge in routine practice.
A meta-analysis that evaluated the efficacy of conventional
IFN and ribavirin combination therapy in previous
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nonresponders reported only 13% SVR, thus indicating the
need for better therapeutic options [8].
We evaluated the efficacy and tolerability of peginterferon
alfa-2a (40KD) plus ribavirin combination therapy in patients
with chronic hepatitis C who had previously failed to respond
or who responded and subsequently relapsed after
conventional IFN plus ribavirin therapy.
Material and Methods
Patients. One hundred and thirty-four patients from 20 to 71
years old with chronic hepatitis C who had previously received
one course of conventional IFN (3-6 MU tiw) plus ribavirin
(800-1200 mg qd) for at least 24 weeks were considered eligible
for this study. Among these, 97 patients never achieved
undetectable HCV RNA levels (qualitative PCR testing) during
the first treatment (nonresponders, group A) and 37 patients
showed undetectable HCV RNA during the first therapy but
became HCV RNA positive after discontinuing medication
(relapsers, group B). At the baseline, the patients were HCV
RNA positive, had elevated ALT (defined as ALT above the
upper limit of normal) and had a liver biopsy consistent with
chronic hepatitis C. Exclusion criteria were previous course of
conventional IFN monotherapy, age below 18 years, HBV or
HIV virus infection, platelet count <75,000cells/mm3, neutrophil
count <1500cells/mm3 and hemoglobin levels <12g/dL, evidence
of decompensated liver disease, alcohol or drug abuse,
metabolic or autoimmune liver disease, severe psychiatric
conditions, seizures, other poorly controlled clinical diseases,
pregnancy or unwillingness to practice contraception.
Study design. This was an open-label non-randomized trial
conducted at 14 Brazilian centers. The study was approved
by the Institutional Ethics Committee of each participating
center and a written informed consent was obtained from every
patient. Enrollment began in 2000 and lasted 18 months. Eligible
patients were consecutively included in the study and
received peginterferon alfa-2a (40KD) (PEGASYS®),
subcutaneously at a dose of 180 mcg/weekly plus ribavirin
(COPEGUS®) administered orally twice a day at a total dose
of 800 mg for 48 weeks (group A nonresponders and group B
relapsers). Clinical and laboratory evaluations were performed
at screening, baseline, week 2, week 4, monthly thereafter, and
at follow-up weeks 4, 12 and 24. All patients had HCV
genotyping before study entry. Qualitative HCV RNA and
HCV RNA quantification were done by in house or Roche
Amplicor methodologies. Liver biopsies were graded
according to METAVIR criteria.
Assessment of efficacy. The primary efficacy end point was
sustained virological response (SVR), defined as the absence
of detectable HCV RNA in serum by polymerase chain reaction
(detection limit of 100 copies per milliliter) 24 weeks after
cessation of treatment. A secondary end point was used to
compare the efficacy of combination therapy in genotype 1
versus non-1 genotype patients (nonresponders and
relapsers), to evaluate the percentage of relapsers (patients
with negative HCV RNA at the end of therapy and a positive
HCV RNA test at the end of follow-up) and to evaluate
predictive variables associated with a better outcome.
Assessment of safety. The safety profile was assessed by
evaluation of adverse events and by laboratory tests. Adverse
events were graded as mild, moderate, severe or life threatening,
according to the modified World Health Organization (WHO)
grading system. Therapy adjustments were allowed and
performed whenever there were changes in hemoglobin, or in
white blood cell or platelet counts, using standard guidelines for
peginterferon alfa-2a (40KD) plus ribavirin combination treatment.
If the abnormalities were resolved, the doses were increased
towards the initial dose. Patients skipping more than four
consecutive treatment weeks were withdrawn from the study. All
patients prematurely withdrawn were followed for safety reasons
during 12 weeks after the last study medication dose.
Statistical analysis. Efficacy analysis was performed on an
intention-to-treat basis; therefore all patients who received at
least one study dose were considered for the primary end
point. Response rate was calculated as the number of patients
with a sustained virological response divided by the number
of patients who started treatment. Patients who did not have
week-24 follow-up assessments were classified as
nonresponders. Comparisons were made at a significance level
of 0.05. Changes from baseline variables were analyzed using
analysis of covariance with the baseline value as a covariate.
The following parameters were examined as potential
prognostic factors for treatment success: gender (male vs
female), age (< 40 years versus > 40 years), viral load (= 800.000
IU versus > 800.000 IU), histological status (no cirrhosis vs
cirrhosis), HCV genotype (1 and 4 versus 2 and 3) and
adherence (adherent versus nonadherent). An exact 95%
confidence interval from the binomial distribution was
determined for each prognostic variable.
Results
Patient characteristics. One-hundred-thirty-four patients
agreed to participate, gave a written informed consent and
were enrolled in the study; 97 nonresponders to previous IFN
treatment were allocated to group A, and 37 relapsers to
previous IFN treatment were allocated to group B. Baseline
demographic, virological and histological characteristics of
patients in the two treatment groups were similar (Table 1).
Overall, 111 (83%) patients were men, median age was 48 years
(range 20-71), 111 (83%) patients were Caucasian, 96 (72%)
patients were genotype 1 and histological evidence of cirrhosis
was observed in 44 (34%) patients. Bridging fibrosis was
observed in 29 (22%) patients. Among patients with non-1
Peg α-2a/RBV HCV Retreatment
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All patients Group A Group B
(n = 134) (n = 97)  (n = 37)
Gender    
Male 111 (83) 81 (84) 30 (81)
Age (years)    
Median (range) 48 (20 - 71) 48 (20 - 71) 50 (28 - 70)
Race    
White 111 (83) 79 (82) 32 (86)
Mulato 18 (13) 13 (13) 5 (14)
Other 5 (4) 5 (5) 0 (0)
Histological diagnosis*    
Noncirrhotic 86 (64) 58 (60) 29  (78)
Cirrhotic 44 (33) 36 (37) 8 (22)
HCV genotype    
1 96 (72) 69 (71) 27 (73)
2 1 (0,7) 1 (1) 0 (0)
3 36 (27) 26 (27) 10 (27)
4 1 (0,7) 1 (1) 0 (0)
Serum HCV RNA    
> 800.000 53 (39) 48 (50) 16 (43)
≤ 800.000 64 (48) 39 (40) 14 (38)
Missing 17 (13) 10 (10) 7 (19)
Group A = nonresponders; Group B = relapsers. Values expressed
as number of patients (percentage). *Data was missing in 3 patients
in group A and in 1 patient in group B.
All patients Group A Group B
(n = 134) (n = 97) (n = 37)
HCV genotype    
Genotype 1 24/96 (25) 12/69 (17) 12/27 (44)
Genotype non-1 20/38 (53) 13/28 (46) 7/10 (70)
Histological diagnosis    
Noncirrhotic 34/90 (38) 20/61 (33) 14/29 (48)
Cirrhotic 8/44 (18) 4/36 (11) 4/8 (50)
Histological diagnosis (genotype 1)    
Noncirrhotic 19/63 (30) 10/42 (24) 9/21 (43)
Cirrhotic 5/33 (15) 2/27 (7) 3/6 (50)
Histological diagnosis (genotype non-1)    
Noncirrhotic 15/27 (56) 10/19 (53) 5/8 (63)
Cirrhotic 3/11 (27) 2/9 (22) 1/2 (50)
Baseline serum HCV RNA    
≤ 800.000 18/51 (35) 8/37 (22) 10/14 (71)
> 800.000 16/64 (25) 10/48 (21) 6/16 (38)
Baseline serum HCV RNA (genotype 1)    
≤ 800.000 10/33 (30) 4/24 (17) 6/9 (67)
> 800.000 9/49 (18) 4/37 (11) 5/12 (42)
Baseline serum HCV RNA (genotype non-1)    
≤ 800.000 8/18 (44) 4/14 (29) 4/4 ( 1 0 0 )
> 800.000 7/15 (47) 6/11 (55) 1/4 (25)
Group A = nonresponders; Group B = relapsers. Values expressed
as number/total number of patients (percentage).
genotype, 1 (1%) was genotype 2, 36 (27%) were genotype 3
and 1 (1%) was genotype 4. HCV RNA quantification was
performed before treatment in 117 patients (87.3%).
Outcomes according to treatment groups. The percentage of
patients with undetectable serum HCV RNA at the end of the
treatment period was 57% in group A (nonresponders) and
78% in group B (relapsers). At the end of follow-up, the rate of
sustained virological response was 26% for group A and 51%
for group B (Table 2).
SVR was more frequent in non-1 genotype compared to
genotype 1 patients (Table 3). In the nonresponders group,
46% of non-1 genotype achieved an SVR (versus 17% for
genotype 1, p = 0.0048), and in the relapsers group, 70% of
non-1 genotype achieved an SVR (versus 44% for genotype
1, p = 0.2691). SVR was also more frequent in non-cirrhotic
compared to cirrhotic patients in nonresponders (group A,
33% versus 11%, p = 0.0269). However SVR was similar in
non-cirrhotic and cirrhotic patients among relapsers (group
B, 48% versus 50%, p = 1.0000). Among nonresponders,
patients with low baseline serum HCV RNA (< 800,000 IU/mL)
showed the same SVR as patients with high baseline serum
HCV RNA (> 800,000 IU/mL, 21% for both). Among relapsers,
patients with low baseline serum HCV RNA showed higher
SVR, when compared to patients with high baseline serum
HCV RNA (71% versus 37%, p = 0.0813). The complete
subgroup analysis is presented in Table 3.
A bivariate logistic regression analysis identified genotype
non-1 (OR 4.02 – CI 1.5-10.5), relapser state (OR 4.2 – CI 1.6-
11.2) and adherence (OR 5.8 – CI 1.8-19), as the significant
baseline variables associated with an SVR.
Safety and tolerability. Overall, 23 patients (17%) prematurely
discontinued treatment. The reasons were adverse events or
laboratory abnormalities in 6 (4.5%) patients, noncompliance
in 8 (6%) patients and absence of response in 9 (6.7%) patients
(Table 4).
Dose reduction because of laboratory abnormalities and/
or adverse events was required in 60 patients (45%), with a
similar proportion among groups A and B. Reasons for dose
Peg α-2a/RBV HCV Retreatment
Table 1. Patients baseline characteristics
Table 2. Virological response rates
HCV RNA clearance All patients Group A Group B
(n = 134) (n = 97)  (n = 37)
End of therapy 84 (63) 55 (57) 29 (78)
  (week 48)
End of follow-up 44 (33) 25 (26) 19 (51)
  (week 72)
Group A = nonresponders; Group B = relapsers. Values expressed
as number of patients (percentage).
Table 3. Patients with sustained virological response as a
function of baseline variables and treatment group
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Table 4. Incidence of discontinuation of treatment and dose
reduction
All patients Group A Group B
(n = 134) (n = 97) (n = 37)
Dose discontinuation for    
Any adverse event 6 (4) 6 (6) 0 (0)
Insufficient response 9 (7) 6 (6) 3 (8)
Lost to follow-up 8 (6) 7  (7) 1  (3)
Dose modification for**    
Any adverse event 60 (45) 40 (41) 20 (54)
Anaemia 6 (4) 4 (4) 2 (5)
Neutropenia 22 (16) 14 (14) 8 (22)
Thrombocytopenia 10 (7) 7 (7) 3 (8)
ALT Elevation 6  (4) 3 (3) 3 (8)
Group A = nonresponders; Group B = relapsers. Values expressed
as number of patients (percentage). †Dose reduction was defined as
the reduction or omission of one or more doses.
‡Some patients required dose reduction for both laboratory
abnormalities and other adverse events.
Figure 1. Virological response rates (end of treatment)
Figure 2. Virological response rates (end of follow-up)
Figure 3. Sustained virological response (genotype 1)
Figure 4. Sustained virological response (genotype non- 1)
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Table 5. Adverse events
Adverse event Group A (n=97) Group B (n=37)
Headache 42 14
Myalgia 31 11
Fever 29 08
Irritability 16 14
Nausea 22 04
Fatigue 16 10
Imsomnia 19 06
Weight loss 19 04
Asthenia 17 05
Malaise 22 07
Depression 14 06
Diarrhea 14 05
Dizziness 13 04
Anorexia 20 08
Cough 09 06
Flu-like 17 09
Pruritus 9 04
Dispepsia 9 04
Anxiety 10 03
* Adverse events that occurred in more than 10% of patients.
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reduction are listed in Table 4. Overall, the most frequent cause
for peginterferon alfa-2a (40KD) dose modification was
neutropenia which occurred in 14 group A patients (14%) and
in 8 group B patients (22%). Ribavirin was reduced mostly
because of hemolytic anemia, which was observed in 4% of
patients from group A and 5% of patients from group B. There
were no severe infection or cardiac events associated with
laboratory abnormalities.
Most of the adverse events reported during treatment
showed the same profile as already known for peginterferon
alfa-2a (40KD) plus RBV, and they were graded as mild or
moderate. Flu-like symptoms was the most common among
the adverse events (Table 5). Both adverse events and
laboratory abnormalities returned to baseline after the
medication was interrupted.
Discussion
Information on the use of peginterferon alfa in patients who
are nonresponders or relapsers to conventional interferon is still
limited. Herrine et al. [9] reported the results of retreating patients
who are relapsers to conventional IFN plus RBV. They found
37% SVR in 32 patients retreated with peginterferon alfa-2a (40KD)
plus ribavirin. An even better SVR was observed in 31 patients
who also received amantadine at a rate of 200 mg/day (45%).
Truly chronic hepatitis C patients who are nonresponders
to conventional IFN plus ribavirin represents one of the most
difficult challenges in clinical routine. Shiffman et al. [10]
reported the first analysis from the HALT-C trial, designed to
look at the histological end points in patients without
virological responses. They examined only nonresponder
patients with advanced fibrosis or cirrhosis (F3/F4) who
received a full 48-week course of peginterferon alfa-2a (40KD)
plus ribavirin. Overall, they found an SVR of 18% (N = 604). In
the nonresponders in the conventional IFN plus ribavirin
group, the SVR was 12%. The non-1 genotype patients had
responses of at least 54%.
We found that nonresponders to at least 24 weeks of
conventional IFN and ribavirin combination therapy achieved
26% of SVR when retreated with peginterferon alfa-2a (40KD)
plus ribavirin for 48 weeks. This result is higher than previously
reported results. On the other hand, our results on relapsers
(SVR of 51%) are quite similar to what was reported by Herrine
et al. [9] (37 to 45%). Probably, the more advanced histological
disease observed among HALT-C patients contributed to
lowering the rates of SVR observed by Shiffman et al. [10].
However, one has to consider that the conventional interferon
normally used in the Brazilian public health services comes
from various countries, with no prospective and controlled
evaluation of virological responses. Observational studies
have suggested that virological responses could be inferior
to those obtained in the registration trials reported by some
investigators [11,12]. This should bring the issue that Brazilian
nonresponders may be an easier group to be retreated
compared to non Brazilian patients, since there is a lack of
quality assurance in the first antiviral therapy in Brazil.
A genotype subanalysis of our studied population showed
that 17% and 44% of genotype 1 nonresponders and relapser
patients, respectively, achieved a SVR. Among the non-1
genotype nonresponders and relapsers, 46% and 70% of
patients achieved a SVR, respectively. The response rate in
our non-1 genotype relapsers group was close to what was
reported for naive patients submitted to the same therapeutic
regimen (84%) [7].
We also found significantly higher response rates in
nonresponder patients without cirrhosis compared to cirrhotic
patients (33% versus 11.%). This difference was not observed
in relapsers (48% versus 50%), in whom histological diagnosis
seemed not to influence treatment outcome. Furthermore, only
7% of genotype 1 nonresponder patients with cirrhosis
achieved SVR, as compared to 50% of relapser patients with
the same characteristics. Therefore, non-1 genotype infection,
along with a relapser state and good adherence, were the best
independent predictive factors to achieve an SVR in our study.
Pretreatment serum HCV RNA levels were not available for
every patient. We observed a higher rate of SVR (71%) in
relapser patients with low baseline serum HCV RNA levels,
when compared to patients with high baseline serum HCV
RNA levels (37%), although there were few patients with such
characteristics in our study. Indeed, this group of patients
had a better chance to respond to their first course of antiviral
therapy. Surprisingly, in the group of nonresponder patients,
baseline viral load did not influence the outcome and SVR
rates were identical in low and high baseline serum HCV RNA
(21%) patients. Sample size error must be considered as an
explanation for these unexpected results.
It is very important to consider that patients in our study
took a low dose of ribavirin (800 mg/day). It is becoming clearer
that SVRs are better when there is a full exposure to ribavirin,
which is particularly important in difficult to treat genotype 1
patients at the beginning of therapy [13]. We believe that if
we had used a higher dose of ribavirin we could have achieved
a better sustained virological response.
Overall, peginterferon alfa-2a (40KD) plus ribavirin as
retreatment for 48 weeks showed the safety and tolerability
profile seen in naive patients. The rate of discontinuation
linked to side effects was 4% in our study, which compares
favorably to 12% observed in a peginterferon alfa-2a (40KD)
plus ribavirin registration trial made with naive patients [7].
Dose reduction rates for adverse events or laboratory
abnormalities were also similar to what was observed in a
naive patients registration trial (45% versus 62%).
In summary, we suggest that Brazilian hepatitis C patients
who are nonresponders and relapsers to conventional IFN
plus ribavirin can be successfully retreated with peginterferon
alfa-2a (40KD) plus ribavirin combination therapy. The safety
profile is acceptable, and non-1genotype, relapser state and
good adherence are important predictive variables for a SVR.
Peg α-2a/RBV HCV Retreatment
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Abbreviation Notes
ALT = alanine aminotransferase. ETVR = end of therapy
virological response. HCV = hepatitis C virus. IFN =
interferon. MU = million units. SVR = sustained virological
response. TIW = three times weekly. WHO = World Health
Organization; RT-PCR = reverse transcription-polymerase-
chain reaction assay. Brazilian Pegasys Cooperative Study
Group: Oliveira A; Chebli J; Villanova M; Lima L; Borges S;
Teixeira R; Gomes A; Silva R; Pereira L.
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